Abstract
The mitogen-activated protein kinase (MAPK) phosphatases (MKPs) are a family of dual-specificity protein phosphatases that dephosphorylate both phospho-threonine and phospho-tyrosine residues in MAP kinases, including the c-Jun N-terminal protein kinase (JNK)/stress-activated protein kinase (SAPK), the p38 MAPK, and the extracellular signal-related kinase (ERK). Since phosphorylation is required for the activation of MAP kinases, dephosphorylation by MKPs inhibits MAPK activity, thereby negatively regulating MAPK signaling. It is known that deregulation of MAPK signaling is the most common alteration in human cancers. Recent studies have suggested that MKPs play an important role not only in the development of cancers, but also in the response of cancer cells to chemotherapy. Thus, understanding the roles of MKPs in the development of cancer and their impact on chemotherapy can be exploited for therapeutic benefits for the treatment of human cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Davis, R. J. (2000). Signal transduction by the JNK group of MAP kinases. Cell, 103, 239–52.
Johnson, G. L., & Lapadat, R. (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 298, 1911–912.
Pearson, G., Robinson, F., Beers Gibson, T., Xu, B., Karandikar, M., Berman, K., et al. (2001). Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocrine Reviews, 22, 153–83.
Chang, L., & Karin, M. (2001). Mammalian MAP kinase signalling cascades. Nature, 410, 37–0.
Kennedy, N. J., & Davis, R. J. (2003). Role of JNK in tumor development. Cell Cycle, 2, 199–01.
Camps, M., Nichols, A., & Arkinstall, S. (2000). Dual specificity phosphatases: A gene family for control of MAP kinase function. FASEB Journal, 14, 6–6.
Dickinson, R. J., & Keyse, S. M. (2006). Diverse physiological functions for dual-specificity MAP kinase phosphatases. Journal of Cell Science, 119(Pt 22), 4607–615.
Kondoh, K., & Nishida, E. (2006). Regulation of MAP kinases by MAP kinase phosphatases. Biochim Biophys Acta, 1773(8), 1227–237.
Zhan, X. L., Wishart, M. J., & Guan, K. L. (2001). Nonreceptor tyrosine phosphatases in cellular signaling: Regulation of mitogen-activated protein kinases. Chemical Reviews, 101(8), 2477–496.
Theodosiou, A., & Ashworth, A. (2002). MAP kinase phosphatases. Genome Biology, 3(7), REVIEWS3009.
Rohan, P. J., Davis, P., Moskaluk, C. A., Kearns, M., Krutzsch, H., Siebenlist, U., et al. (1993). PAC-1: A mitogen-induced nuclear protein tyrosine phosphatase. Science, 259(5102), 1763–766.
Muda, M., Boschert, U., Smith, A., Antonsson, B., Gillieron, C., Chabert, C., et al. (1997). Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4. Journal of Biological Chemistry, 272(8), 5141–151.
Lau, L. F., & Nathans, D. (1985). Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells. EMBO Journal, 4(12), 3145–151.
Charles, C. H., Abler, A. S., & Lau, L. F. (1992). cDNA sequence of a growth factor-inducible immediate early gene and characterization of its encoded protein. Oncogene, 7, 187–90.
Keyse, S. M., & Emslie, E. A. (1992). Oxidative stress and heat shock induce a human gene encoding a protein’tyrosine phosphatase. Nature, 359, 644–47.
Li, J., Gorospe, M., Hutter, D., Barnes, J., Keyse, S. M., & Liu, Y. (2001). Transcriptional induction of MKP-1 in response to stress is associated with histone H3 phosphorylation’acetylation. Molecular and Cellular Biology, 21, 8213–224.
Liu, Y., Gorospe, M., Yang, C., & Holbrook, N. J. (1995). Role of mitogen-activated protein kinase phosphatase during the cellular response to genotoxic stress. Inhibition of c-Jun N-terminal kinase activity and AP-1-dependent gene activation. Journal of Biological Chemistry, 270(15), 8377–380.
Zhou, J. Y., Liu, Y., & Wu, G. S. (2006). The role of mitogen-activated protein kinase phosphatase-1 in oxidative damage-induced cell death. Cancer Research, 66(9), 4888–894.
Wang, Z., Xu, J., Zhou, J. Y., Liu, Y., & Wu, G. S. (2006). Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Research, 66(17), 8870–877.
Sun, H., Charles, C. H., Lau, L. F., & Tonks, N. K. (1993). MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell, 75, 487–93.
Noguchi, T., Metz, R., Chen, L., Mattei, M. G., Carrasco, D., & Bravo, R. (1993). Structure, mapping, and expression of erp, a growth factor-inducible gene encoding a nontransmembrane protein tyrosine phosphatase, and effect of ERP on cell growth. Molecular and Cellular Biology, 13, 5195–205.
Franklin, C. C., & Kraft, A. S. (1997). Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. Journal of Biological Chemistry, 272, 16917–6923.
Brondello, J. M., McKenzie, F. R., Sun, H., Tonks, N. K., Pouyssegur, J. (1995). Constitutive MAP kinase phosphatase (MKP-1) expression blocks G1 specific gene transcription and S-phase entry in fibroblasts. Oncogene, 10, 1895–904.
Li, M., Zhou, J. Y., Ge, Y., Matherly, L. H., & Wu, G. S. (2003). The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. Journal of Biological Chemistry, 278, 41059–1068.
Yang, H., & Wu, G. S. (2004). p53 Transactivates the phosphatase MKP1 through both intronic and exonic p53 responsive elements. Cancer Biology and Therapy, 3(12), 1277–282.
Wu, G. S. (2004). The Functional Interactions Between the p53 and MAPK Signaling Pathways. Cancer Biology and Therapy, 3, 156–61.
Franklin, C. C., Srikanth, S., & Kraft, A. S. (1998). Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. Proceedings of the National Academy of Sciences, U.S.A., 95, 3014–019.
Sanchez-Perez, I., Martinez-Gomariz, M., Williams, D., Keyse, S. M., & Perona, R. (2000). CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene, 19, 5142–152.
Wu, J. J., & Bennett, A. M. (2005). Essential role for MAP kinase phosphatase-1 in stress-responsive MAP kinase and cell survival signaling. Journal of Biological Chemistry, 280, 16461–6466.
Chattopadhyay, S., Machado-Pinilla, R., Manguan-Garcia, C., Belda-Iniesta, C., Moratilla, C., Cejas, P., et al. (2006). MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene, 25(23), 3335–345.
Dorfman, K., Carrasco, D., Gruda, M., Ryan, C., Lira, S. A., & Bravo, R. (1996). Disruption of the erp/mkp-1 gene does not affect mouse development: Normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene, 13, 925–31.
Wang, H. Y., Cheng, Z., & Malbon, C. C. (2003). Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Letters, 191(2), 229–37.
Loda, M., Capodieci, P., Mishra, R., Yao, H., Corless, C., Grigioni, W., et al. (1996). Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. American Journal of Pathology, 149(5), 1553–564.
Vicent, S., Garayoa, M., Lopez-Picazo, J. M., Lozano, M. D., Toledo, G., Thunnissen, F. B., et al. (2004). Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clinical Cancer Research, 10(11), 3639–649.
Denkert, C., Schmitt, W. D., Berger, S., Reles, A., Pest, S., Siegert, A., et al. (2002). Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. International Journal of Cancer, 102(5), 507–13.
Manzano, R. G., Montuenga, L. M., Dayton, M., Dent, P., Kinoshita, I., Vicent, S., et al. (2002). CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene, 21(28), 4435–447.
Rauhala, H. E., Porkka, K. P., Tolonen, T. T., Martikainen, P. M., Tammela, T. L., & Visakorpi, T. (2005). Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer. International Journal of Cancer, 117(5), 738–45.
Liao Q., Guo J., Kleeff J., Zimmermann, A., Büchler, M. W., Korc, M., et al. (2003). Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology, 124(7), 1830–845.
Tsujita, E., Taketomi, A., Gion, T., Kuroda, Y., Endo, K., Watanabe, A., et al. (2005). Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma. Oncology, 69(4), 342–47.
Yokoyama, A., Karasaki, H., Urushibara, N., Nomoto, K., Imai, Y., Nakamura, K., et al. (1997). The characteristic gene expressions of MAPK phosphatases 1 and 2 in hepatocarcinogenesis, rat ascites hepatoma cells, and regenerating rat liver. Biochemical and Biophysical Research Communications, 239(3), 746–51.
Bang, Y. J., Kwon, J. H., Kang, S. H., Kim, J. W., & Yang, Y. C. (1998). Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma. BBRC, 250(1), 43–7.
Groom, L. A., Sneddon, A. A., Alessi, D. R., Dowd, S., & Keyse, S. M. (1996). Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO Journal, 15(14), 3621–632.
Muda, M., Boschert, U., Dickinson, R., Martinou, J.-C., Martinou, I., Camps, M., et al. (1996). MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. Journal of Biological Chemistry, 271(8), 4319–326.
Kawakami, Y., Rodriguez-Leon, J., Koth, C. M., Büscher, D., Itoh, T., Raya, A., et al. (2003). MKP3 mediates the cellular response to FGF8 signalling in the vertebrate limb. Nature Cell Biology, 5(6), 513–19.
Furukawa, T., Sunamura, M., Motoi, F., Matsuno, S., & Horii, A. (2003). Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. American Journal of Pathology, 162(6), 1807–815.
Furukawa, T., Fujisaki, R., Yoshida, Y., Kanai, N., Sunamura, M., Abe, T., et al. (2005). Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary’mucinous neoplasms of the pancreas. Modern Pathology, 18(8), 1034–042.
Xu, S., Furukawa, T., Kanai, N., Sunamura, M., & Horii, A. (2005). Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. Journal of Human Genetics, 50(4), 159–67.
Marchetti, S., Gimond, C., Roux, D., Gothie, E., Pouyssegur, J., & Pages, G. (2004). Inducible expression of a MAP kinase phosphatase-3-GFP chimera specifically blunts fibroblast growth and ras-dependent tumor formation in nude mice. Journal of Cellular Physiology, 199(3), 441–50.
Chen, H. Y., Yu, S. L., Chen, C. H., Chang, G.-C., Chen, C.-Y., Yuan, A., et al. (2007). A five-gene signature and clinical outcome in non-small-cell lung cancer. New England Journal of Medicine, 356(1), 11–0.
Givant-Horwitz, V., Davidson, B., Goderstad, J. M., Nesland, J. M., Trope, C. G., & Reich, R. (2004). The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecologic Oncology, 93(2), 517–23.
Sieben, N. L., Oosting, J., Flanagan, A. M., Prat, J., Roemen,G. M. J. M., Kolkman-Uljee, S. M., et al. (2005). Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. Journal of Clinical Oncology, 23(29), 7257–264.
Levy-Nissenbaum, O., Sagi-Assif, O., Kapon, D., Hantisteanu, S., Burg, T., Raanani, P., et al. (2003). Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells. Oncogene, 22(48), 7649–660.
Levy-Nissenbaum, O., Sagi-Assif, O., Raanani, P., Avigdor, A., Ben-Bassat, I., & Witz, I. P. (2003). Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. Cancer Letters, 199(2), 185–92.
Srikanth, S., Franklin, C. C., Duke, R. C., & Kraft, A. S. (1999). Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Molecular and Cellular Biochemistry, 199, 169–78.
Orlowski, R. Z., Small, G. W., & Shi, Y. Y. (2002). Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. Journal of Biological Chemistry, 277(31), 27864–7871.
Small, G. W., Shi, Y. Y., Edmund, N. A., Somasundaram, S., Moore, D. T., & Orlowski, R. Z. (2004). Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Molecular Pharmacology, 66(6), 1478–490.
Wu, W., Chaudhuri, S., Brickley, D. R., Pang, D., Karrison, T., & Conzen, S. D. (2004). Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Research, 64(5), 1757–764.
Wu, W., Pew, T., Zou, M., Pang, D., & Conzen, S. D. (2005). Glucocorticoid receptor-induced MAPK phosphatase-1 (MKP-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. Journal of Biological Chemistry, 280(6), 4117–124.
Cui, Y., Parra, I., Zhang, M., Hilsenbeck, S. G., Tsimelzon, A., Furukawa, T., et al. (2006). Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: A mechanism of tamoxifen resistance. Cancer Research, 66(11), 5950–959.
Vogt, A., Cooley, K. A., Brisson, M., Tarpley, M. G., Wipf, P., & Lazo, J. S. (2003). Cell-active dual specificity phosphatase inhibitors identified by high-content screening. Chemistry and Biology, 10(8), 733–42.
Lazo, J. S., Nunes, R., Skoko, J. J., Queiroz de Oliveira, P. E., Vogt, A., & Wipf, P. (2006). Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1. Bioorganic & Medicinal Chemistry, 14(16), 5643–650.
Vogt, A., Tamewitz, A., Skoko, J., Sikorski, R. P., Giuliano, K. A., & Lazo, J. S. (2005). The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. Journal of Biological Chemistry, 280(19), 19078–9086.
Arnold, D. M., Foster, C., Huryn, D. M., Lazo, J. S., Johnston,P. A., & Wipf, P. (2007). Synthesis and biological activity of a focused library of mitogen-activated protein kinase phosphatase inhibitors. Chemical Biology and Drug Design, 69(1), 23–0.
Chen, P., Li, J., Barnes, J., Kokkonen, G. C., Lee, J. C., & Liu, Y. (2002). Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. Journal of Immunology, 169, 6408–416.
Wang, X., Matta, R., Shen, G., Nelin, L. D., Pei, D., & Liu, Y. (2006). Mechanism of triptolide-induced apoptosis: Effect on caspase activation and Bid cleavage and essentiality of the hydroxyl group of triptolide. Journal of Molecular Medicine, 84(5), 405–15.
Gonzalez-Santiago, L., Suarez, Y., Zarich, N., Muñoz-Alonso,M. J., Cuadrado, A., Martínez, T., et al. (2006). Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death and Differentiation, 13(11), 1968–981.
Author information
Authors and Affiliations
Corresponding author
Additional information
This paper received support from NIH grant R01 CA100073 and Elsa U. Pardee Foundation.